KALU

Kaiser has executed a clean cyclical recovery: after losing money in FY2021 (-$18.5M) and FY2022 (-$29.6M), it has strung together three profitable years, capped by FY2025 net income of $113M (+71.2%) on revenue of $3.37B (+11.5%) and diluted EPS of $6.77 (+68.4%). The MD&A reframes the business correctly — headline 'Net sales' are inflated by pass-through metal cost under management's 'metal price neutrality' model, so the real top line is Conversion Revenue of $1.45B, against which Adjusted EBITDA of $310.2M is a healthy ~21% margin. ROE of 13.6% and a fully covered $3.08/share dividend round out a genuinely improved operation. On EV/EBITDA (~$3.6B EV / $310M ≈ 11.6x) the stock looks reasonable for a recovering industrial.

The problem is what you pay and what it earns in cash. At $187.16 the trailing P/E is 27.6x — a full multiple for a cyclical with razor-thin reported margins (5.6% operating, 3.3% net) whose earnings can swing hard with shipment volumes and alloy-price resets that the firm itself flags can run adverse 'until the selling price resets.' More telling, FY2025 operating cash flow fell 33% to $111M while capex stayed elevated at $137M, so free cash flow was negative (~-$26M), and the $51.3M dividend was funded from the balance sheet, not from earnings cash. Reported cash is just $7.0M (down 62%); liquidity rests on the $547.2M combined cash-plus-revolver line cited in the MD&A. Leverage is meaningful at 2.10x liabilities/equity with $1.06B long-term debt, and the firm just refinanced its 4.625% 2028 notes into 5.875% 2034 notes — extending maturity but raising the coupon ~125bp, a headwind to future interest expense.